CELL & GENE THERAPY INSIGHTS

Vector bioprocessing

Guest Editor:
Franz Gerner, Chief Technology Officer at Excision BioTherapeutics
Franz Gerner
Chief Technology Officer at Excision BioTherapeutics
April 2022